The FDA has recently disclosed a statement that the popular heartburn medication Zantac contained small amounts of N-nitrosodimethylamine (NDMA). The Zantac NDMA contamination has drawn the ongoing attention of the FDA as they examine the implications of the contaminant’s exposure to consumers.
Ranitidine medicines, most commonly known by the brand name Zantac, are a group of drugs used as histamine-2 blockers to decrease stomach acid in users. The FDA became aware of the Zantac NDMA contamination after low levels of NDMA were detected in small amounts.
While NDMA is currently classified as a probable human carcinogen based on laboratory studies, NDMA is also an environmental contaminant found in water, meats, dairy, and vegetables. The FDA is currently looking into the potential harms of low-level NDMA exposure but has emphasized that the Zantac NDMA contamination is minor and they do not encourage patients to stop using Zantac or other ranitidine medicines.
At this time, due to the Zantac NDMA contamination levels being approximately equal to the levels typically found in almost all foods and water across the nation, the FDA has suggested that patients who are uncomfortable using Zantac to switch to a heartburn medication that is not ranitidine-based. Otherwise, the FDA has stated that NDMA may cause harm in large amounts, but the Zantac NDMA contamination levels are low by any standard.
If you or a loved one have been negatively affected by a prescription medication or an over-the-counter drug, visit Parker Waichman’s Defective Drugs Page to explore compensatory options.
If you or a loved one have experienced severe side effects as the result of an ineffective or wrongly prescribed medication, compensation may be available to you. At Parker Waichman LLP, teams of experienced trial attorneys are prepared to pursue your case to its fullest extent. Don’t wait. Contact Parker Waichman today and begin your journey for compensation.